Denis L. Sibilot-Moro

Denis L. Sibilot-Moro

La Tronche, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 184 publications

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Journal: The New England journal of medicine

Published: May 29, 2026

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.

Journal: The New England journal of medicine

Published: May 29, 2026

PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.

PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients.

Journal: Frontiers in immunology

Published: December 08, 2025

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST Study.

Journal: Oncology and therapy

Published: July 22, 2025

Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".

Response to letter Re "Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS".

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 11, 2025

MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.

MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial.

Journal: Translational oncology

Published: June 09, 2025

Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.

Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.

Journal: ESMO open

Published: May 27, 2025

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.

Journal: Oncoimmunology

Published: April 15, 2025

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers.

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers.

Journal: Oncoimmunology

Published: April 07, 2025

New perspectives in the management of small cell bronchial cancer

New perspectives in the management of small cell bronchial cancer

Journal: Bulletin du cancer

Published: March 28, 2025

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.

Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 21, 2025

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.

RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 09, 2024

Showing 1-12 of 184

Last Updated: 09/26/2026